The place of targeted therapy in the patient management of non-small cell lung cancer.

The place of targeted therapy in the patient management of non-small cell lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The place of targeted therapy in the patient management of non-small cell lung cancer. Abstract Text:

Nicholas Thatcher,

There is much interest in the use of targeted therapies for the management of non-small cell lung cancer (NSCLC). To date, four targeted therapies - bevacizumab, cetuximab, erlotinib and gefitinib - have been investigated in randomised trials, in the treatment of advanced NSCLC. In the first-line setting, bevacizumab has been shown to significantly prolong survival when added to carboplatin/paclitaxel, as demonstrated in a large phase III study. However, issues of toxicity limit this treatment regimen to selected patients. The addition of bevacizumab to gemcitabine/cisplatin will be reported at ASCO 2007. The addition of cetuximab to cisplatin/vinorelbine has also been shown to improve survival in a randomised phase II study. Erlotinib has been investigated as monotherapy in first-line chemo-naïve patients and has demonstrated objective response rates of 10-23%. However, in a study comparing erlotinib versus chemotherapy, the outcome was less favourable for patients who had received erlotinib. Erlotinib monotherapy has also been investigated in recurrent disease, and has been shown to improve overall survival over that achieved with placebo. The greatest benefit was observed in never-smokers with epidermal growth factor receptor-positive tumours. In a further phase II randomised study, the effect of combining two targeted therapies has been investigated. This study compared erlotinib/bevacizumab versus bevacizumab/chemotherapy versus chemotherapy alone. Both regimens including targeted therapy were comparable and superior to chemotherapy alone. However, these are preliminary data and further research is required to clarify the role of targeted therapies in the management of advanced NSCLC.

The place of targeted therapy in the patient management of non-small cell lung cancer. Publishing Authors By Initials

N Thatcher,

For similar heterocyclic compounds: heterocyclic compounds, 2-ring: quinazolines research abstracts see: heterocyclic compounds: heterocyclic compounds, 2-ring: quinazolines research

PUBMED ID PMID:

MEDLINE DATE:

The place of targeted therapy in the patient management of non-small cell lung cancer. Journal Published:

PUBLICATION TYPE: Review

Journal: Lung cancer (Amsterdam, Netherlands)

VOLUME: 57 Suppl 2

Page Numbers: S18-23

Journal Abbreviation: Lung Cancer

ISSN: 0169-5002

DAY: 29

MONTH: Aug

YEAR: 2007

The place of targeted therapy in the patient management of non-small cell lung cancer. Information

Number of References: 21

LANGUAGE: eng

NlmUniqueID: 8800805

The place of targeted therapy in the patient management of non-small cell lung cancer. Keywords Mesh Terms:

KEYWORDS: Quinazolines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: The place of targeted therapy in the patient management of non-small cell lung cancer. Information

Substance Name: gefitinib

Registry Number: 184475-35-2

Grant and Affiliation Information for The place of targeted therapy in the patient management of non-small cell lung cancer.

AFFILIATION: Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M204BX, UK. Nick.Thatcher2@christie.nhs.uk

Country: Ireland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Lung Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The place of targeted therapy in the patient management of non-small cell lung cancer Related Publications

• Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells.
• Antibiotics in foods: a review of some public health aspects.
• Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
• Cloned ovarian cells from sheep: Cholesterol dependency in progesterone synthesis.
• Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo.
• Concentration of phenylbutazone (PBZ) and 13, 14-dihydro-15 keto PGF(2alpha) (PGFM) in blood and seminal plasma of stallions treated with PBZ.
• Cortical reorganization in deaf children.
• Effects of calving-related disorders on prostaglandin, calcium, ovarian activity and uterine involution in postrartum dairy cows.
• Effects of dietary unsaturated fatty acids on oocyte quality and follicular development in lactating dairy cows in summer.
• Effects of postinsemination progesterone supplementation on fertility and subsequent estrous responses of dairy heifers.
• Embryonic development in superovulated dairy cattle exposed to elevated ambient temperatures between Days 1 to 7 post insemination.
• Fetal survival in the cow after pregnancy diagnosis by palpation per rectum.
• Follicular dynamics and superovulatory response in Holstein cows treated with FSH-P in different endocrine states.
• HEALTH PROBLEMS IN THE FOOD INDUSTRY.
• Influence of summer heat stress on pregnancy rates of lactating dairy cattle following embryo transfer or artificial insemination.
• Influences of in vitro oocyte aging on microfertilization in the mouse with reference to zona hardening.
• Potential mechanisms of estrogen quinone carcinogenesis.
• Pregnancy, bovine somatotropin, and dietary n-3 Fatty acids in lactating dairy cows: III. Fatty acid distribution.
• Pregnancy, bovine somatotropin, and dietary n-3 fatty acids in lactating dairy cows: I. Ovarian, conceptus, and growth hormone-insulin-like growth factor system responses.
• Pregnancy, bovine somatotropin, and dietary n-3 fatty acids in lactating dairy cows: II. Endometrial gene expression related to maintenance of pregnancy.
• Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection.
• Regulation of heat shock-induced alterations in the release of prostaglandins by the uterine endometrium of cows.
• Secretion of PGF2alpha and oxytocin during hyperthermia in cyclic and pregnant heifers.
• Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
• Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
• Survival improvement in thoracic cancer: progress from the last decade and beyond.
• The effects of ACTH on the renin-aldosterone system in normotensive man.
• The long-term pattern of adult mortality and the highest attained age.
• The place of targeted therapy in the patient management of non-small cell lung cancer.
• The role of potassium as cause of death in experimental trypanosomiasis.